DRG Market Assessment reports

Although tumor necrosis factor-alpha (TNF-α) inhibitors remain the most widely prescribed biologics for rheumatoid arthritis (RA) patients refractory to conventional DMARD treatment (the first-…

Rheumatoid arthritis (RA) is a chronic and progressive autoimmune disease that primarily affects the joints. China has the highest number of RA patients in the world, and disease management is…

Rheumatoid arthritis (RA) patients who are refractory to one or more tumor necrosis factor-alpha (TNF-α) inhibitors are generally prescribed a non-TNF-targeted therapy (e.g., Bristol Myers Squibb…

The treatment of rheumatoid arthritis (RA) typically begins with cost-effective conventional DMARDs (cDMARDs), such as methotrexate or hydroxychloroquine. For patients who fail cDMARD treatment or…

Clarivate Epidemiology’s coverage of rheumatoid arthritis (RA) pain comprises epidemiological estimates of key patient populations in the major mature pharmaceutical markets (the United States,…

Clarivate Epidemiology’s coverage of rheumatoid arthritis (RA) pain comprises epidemiological estimates of key patient populations in the major mature pharmaceutical markets (the United States,…

Clarivate Epidemiology’s coverage of rheumatoid arthritis (RA) comprises epidemiological estimates of key patient populations in 45 countries worldwide. We report the prevalence of RA for each…

Clarivate Epidemiology’s coverage of rheumatoid arthritis (RA) comprises epidemiological estimates of key patient populations in 45 countries worldwide. We report the prevalence of RA for each…

Clarivate Epidemiology’s coverage of rheumatoid arthritis (RA) comprises epidemiological estimates of key patient populations in 45 countries worldwide. We report the prevalence of RA for each…

Clarivate Epidemiology’s coverage of rheumatoid arthritis (RA) comprises epidemiological estimates of key patient populations in 45 countries worldwide. We report the prevalence of RA for each…

Clarivate Epidemiology’s coverage of rheumatoid arthritis (RA) comprises epidemiological estimates of key patient populations in 45 countries worldwide. We report the prevalence of RA for each…

Although the tumor necrosis factor-alpha (TNF-α) inhibitors remain the most widely prescribed biologics for rheumatoid arthritis (RA) patients refractory to conventional DMARD treatment (the first…